BioSpace News Archive

Policy

Theravance Biopharma Highlights Marketing Authorization in Europe for Trelegy Ellipta as Once-Daily Single Inhaler Triple Therapy for the Treatment of COPD

Trelegy Ellipta is a product in which Theravance Biopharma has an economic interest in future payments that may be made by Glaxo or one of its affiliates pursuant to its agreements with Innoviva.

November 16, 2017

·

8 min read

Drug Development

Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase II Clinical Trial Designed to Meet Requirements of Regulatory Filing in Japan

Netarsudil ophthalmic solution 0.02% is known by the name Rhopressa in the United States.

November 16, 2017

·

8 min read

Pharm Country

Teleflex Incorporated Announces Pricing of $500M Senior Notes Offering

The sale of the Notes is expected to close on November 20, 2017, subject to customary closing conditions.

November 16, 2017

·

3 min read

Business

Epicore BioNetworks Reports Results for Q1 Fiscal Year 2018 for the Quarter Ended 30 September 2017, in U.S. dollars

Revenue for Q1 at $2.8M was 15% higher than last year’s Q1, setting a new Q1 sales record.

November 16, 2017

·

5 min read

Ampio Pharma Announces Continued Listing Plan Accepted by NYSE American

Ampio Pharmac today announced the receipt of notification that the Company’s plan to regain compliance with the NYSE American’s continued listing standards has been accepted by the NYSE American.

November 16, 2017

·

3 min read

Drug Development

Innovation Pharmaceuticals Offers Perspectives on Brilacidin as a Potential Preventative Treatment for Oral Mucositis in Head and Neck Cancer Patients

The Phase 2 randomized, placebo-controlled clinical trial of Brilacidin-OM, enrolled a total of 61 patients.

November 16, 2017

·

8 min read

FDA

Sonoma Pharmaceuticals Announces FDA Approval of Expanded Indication for Alevicyn to Add Antimicrobial Language

The expanded approval is for the company’s Alevicyn Dermal Spray, to include antimicrobial language and antimicrobial data against clinically relevant microorganisms.

November 16, 2017

·

4 min read

Drug Development

KemPharm Completes Successful End-of-Phase II Meeting on KP415 With FDA

KemPharm held the EOP2 meeting with the FDA to discuss the status of the proposed clinical, non-clinical and abuse liability studies.

November 16, 2017

·

5 min read

Leaders in Technology and Drug Development Collaborate at CNS Summit 2017 to Shape the Future of Clinical Development

Leaders in technology and drug development are meeting at CNS Summit 2017 to collaborate on initiatives and programs to shape the future of clinical development.

November 16, 2017

·

1 min read

Deals

Arcturus Therapeutics Announces Completion of Merger With Alcobra and Commences Trading on the Nasdaq Global Market

The combined company has net cash of approximately $50.1 million, following the merger.

November 16, 2017

·

6 min read